secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMGEN INC (AMGN)
CIK:        0000318154
Form:       8-K
Filed at:   2023-04-27T23:59:59+00:00
Accession:  0000318154-23-000026
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amgen Q1 2023: Revenue $6.1B (-2%); GAAP EPS $5.28; non-GAAP EPS $3.98 (-6%)
----------------------------------------------------------------------------

- Total revenues $6.1B (-2% YoY); product sales +2% with 14% volume growth; ex-U.S. volume grew 22%.
- GAAP EPS $5.28 (+97% YoY) on BeiGene mark-to-market gain; non-GAAP EPS $3.98 (-6%) driven by higher R&D.
- GAAP operating income $1.9B (32.9% margin); non-GAAP operating income $2.8B (48.3% margin).
- Free cash flow $0.7B vs $2.0B in Q1 2022, due to payment timing and higher capex for new facilities.
- CEO reaffirms planned closing of Horizon Therapeutics acquisition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318154/000031815423000026/0000318154-23-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318154/000031815423000026/amgn-20230427.htm
  HTML page:      https://secwatch.observer/filing/0000318154-23-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer